PGop

[PGop @pradgop]

@cune0108 That's still high with a 20x P/S, but then they have cash to back that MC

[PGop @pradgop]

@anidesh7 The insider lockout should've ended on 25th Jan tho $RGTI, so expect a filing from the insiders

[PGop @pradgop]

@kiwicarrotcake I was expecting a $djt short lol when I read the "f*** it"

[PGop @pradgop]

$rgti $qubt $ionq

[PGop @pradgop]

getting killed on my $qubt $rgti short but the gif is funny

[PGop @pradgop]

@bluejaunt100 @MSollender Why was the KOR thesis considered sketchy even before this readout?

[PGop @pradgop]

@jesse_brodkin exactly, should there technically be 0 patients <20 from their inclusion criteria?

[PGop @pradgop]

why are the MMSEs diff between the article and the presentation? $avxl 1/

[Jesse Brodkin @jesse_brodkin]

@ALABASTER_APE_X Not the biggest deal, but probably worthy of some digging 🤔

[PGop @pradgop]

$avxl we see stat sig but are these effect sizes actually meaningful? 4/

[PGop @pradgop]

$avxl still not much clarity on the extra 4 patients between wks 36 & 48. Seems to stem from the 30mg group 3/

[PGop @pradgop]

@S775738 Where is this document from? Can you post a link?

[PGop @pradgop]

$huma he also gave $sava a 116 PT btw

[James DePorre @RevShark]

$HUMA Humacyte price target raised to $15 from $12 at H.C. Wainwright H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Humacyte to $15 from $12 and keeps a Buy rating on the shares after the FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.

[PGop @pradgop]

@NotAnother_Furu @GroupProduct861 @Matteotopi Synthetic short with a call hedge probably

[PGop @pradgop]

Surprising that $qubt insiders haven't sold anything yet on this rally

[PGop @pradgop]

@SuperDuperDrugs @MartinShkreli

[PGop @pradgop]

$galt

[PGop @pradgop]

@NickBlasio shorting it with synthetics as borrow left, puts pretty expensive in both dec & jan $galt

[PGop @pradgop]

@Biotenic shorting it with synthetics as there are no shares left to borrow, might explain the sky high OI for the 2.5 strike

[PGop @pradgop]

$vfc pr for the second investor day should be out soon. More clarity on brand level progress expected